Cordyceps Militaris Capsule Trial Protocol for COPD Patients

A study protocol for a multi-center, randomized, double-blind, placebo-controlled clinical trial involving 160 patients aged 40-85 with mild-to-moderate stable COPD. The trial evaluates the efficacy and safety of Cordyceps militaris capsules versus placebo over a 24-week treatment and 24-week follow-up period. The protocol was authored by Siqi Lin and last updated on 2026-05-25.

Use Cases

• Analyzing clinical trial design for herbal interventions based on the described double-blind, placebo-controlled methodology.
• Studying lung function outcome measures in COPD based on primary and secondary endpoints like FEV1, FVC, and MMEF.
• Evaluating patient-reported outcomes in chronic disease trials based on the inclusion of CAT, CASA-Q, EQ-5D-5L, and mMRC scales.

Strengths

• The protocol is registered with a public clinical trial registry (ChiCTR2400086743), providing a verifiable source.
• The study design is explicitly detailed, including a 1:1 randomization of 160 participants and a 48-week total study period.
• Outcome measures are comprehensively listed, covering lung function parameters, exacerbation frequency, and quality-of-life questionnaires.

Limitations

• The dataset is a 213.7 KB DOCX file containing a study protocol, not the underlying patient-level trial data.
• Column-level documentation for any potential accompanying data is absent; field semantics must be inferred after download.
• Row count for any associated data is unknown, which may limit suitability assessment.

Provenance

Source

figshare, authored by Siqi Lin.

Collection Method

Describes a planned clinical trial protocol.

Time Range

The protocol document was last updated in 2026. The described trial's temporal coverage is not specified.

Freshness

Last updated 2026-05-25 06:07:16; freshness should be verified.

Geography

The trial is described as multi-center, but specific geographic locations are not provided.